Lynch Syndrome Clinical Trial
Official title:
High Definition Endoscopy Versus Virtual Chromoendoscopy In The Detection Of Colonic Polyps In HNPCC
Hereditary non-polyposis colon carcinoma (HNPCC or Lynch-Syndrome) is a rare cause of colorectal cancer caused by a gene defect in the so -called mismatch repair genes. Patients can present at young age with colorectal cancer and polyps can develop faster to malignant lesions in comparison to classical sporadic adenomas. New advanced imaging modalities with high definition images and virtual chromoendoscopy have a theoretical advantage to improve detection and to increase polyp detection. In patients with HNPCC polyp detection has been shown to be increased by classical chromo-endoscopy and by high definition endoscopy with narrow band imaging (NBI) (a virtual chromo-endoscopy modality activated by a button on the endoscope), in comparison to white light endoscopy. However, in these back-to-back studies there was no randomization for the order of imaging modality. It is therefore not clear whether really the image enhancement adds to increased polyp detection or if this is achieved by a second inspection of the mucosa. In this trial the investigators want to assess the real additional value of virtual chromo-endoscopy for polyp detection in patients with the Lynch syndrome. The investigators will use the high definition pentax system and will compare white light endoscopy to i-scan, the incorporated virtual chromo-endoscopy mode in this system.
Hereditary non-polyposis colon carcinoma (HNPCC) or the Lynch syndrome is a rare cause of
colorectal cancer caused by a defect in mismatch repair genes. Because of this, colorectal
cancer does not develop according to the classical adenoma-carcinoma sequence, resulting in
faster progression to malignant lesions. As a results patients typically present at a younger
age with colorectal cancer or associated cancers such as endometrium or ovarian cancer. The
risk for cancer in patients with the Lynch syndrome has been estimated to be 60-90% for colon
cancer presenting at a mean age of 44 years . Colonoscopy is considered the gold standard for
polyp detection. However the polyp miss rate has been reported to be 2% for larger adenomas
(< 10mm) , 13% for lesions between 5 and 10 mm and up to 26% for small lesions (1-5 mm).
Between 2 to 6 percent of carcinomas can be missed , resulting interval cancers. Typically,
in HNPCC small colorectal lesions can already harbor cancer or high grade dysplasia, making
early detection of small lesions even more clinically relevant than in an average risk
population.
New endoscopic imaging systems that are currently available have a high definition video
signal and have an incorporated feature of virtual chromoendoscopy. High definition endoscopy
is becoming the new gold standard in endoscopy, since it is available in all new types of
commercially available endoscopes. The use of high definition endoscopy may lead to improved
recognition of subtle and flat lesions. Furthermore, the use of filters techniques
accentuates superficial changes in the mucosal architecture and helps to characterize polyps.
I-scan is a postprocessing filter incorporated in the high definition processor (EPKi) of the
new Pentax endoscopes. The techniques highlights changes in surface and vessel architecture
through 3 different modifications (so called surface enhancement, tone enhancement and
contrast enhancement). In a randomized trial in patients with a positive feces occult blood
test it has been shown that the system detects significantly more polyps than standard
resolution white light.
Current literature suggests that classical chromoendoscopy with indigocarmine (Huneberg,
lecomte) or narrow-band imaging (NBI) increases the detection of polyps in HNPCC patients.
Although all of these studies had a cross-over design, randomization for the imaging modality
was either not possible (in case of chromoendoscopy) or not applied (in case of NBI). So it
is not clear whether more polyps are detected by advanced imaging techniques, or simply by a
second inspection of the colon.
The aim of this study was to assess the additional value of i-scan in polyp detection in
HNPCC patients in comparison to high definition white light endoscopy (HD-WLE) in a
randomized controlled cross-over trial. The investigators also wanted to investigate the
effect of a second inspection round on polyp detection.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00217737 -
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
|
Phase 3 | |
Completed |
NCT00905710 -
Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome
|
N/A | |
Active, not recruiting |
NCT02194387 -
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
|
N/A | |
Recruiting |
NCT04909671 -
Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome.
|
N/A | |
Recruiting |
NCT04379999 -
Atorvastatin ± Aspirin in Lynch Syndrome Syndrome
|
Early Phase 1 | |
Recruiting |
NCT05692596 -
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
|
||
Completed |
NCT01845753 -
Molecular Screening for Lynch Syndrome in Denmark
|
||
Completed |
NCT01216930 -
Molecular Screening for Lynch Syndrome in Southern Denmark
|
N/A | |
Not yet recruiting |
NCT05963191 -
CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome
|
N/A | |
Active, not recruiting |
NCT02912559 -
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
|
Phase 3 | |
Recruiting |
NCT04978350 -
Overcoming Barriers to the Uptake of Cascade Screening for Lynch Syndrome: Workbook Feasibility Study
|
N/A | |
Active, not recruiting |
NCT03832985 -
Pediatric Reporting of Adult-Onset Genomic Results
|
Early Phase 1 | |
Withdrawn |
NCT04778566 -
Evaluating the Cologuard Test for Use in Lynch Syndrome
|
||
Completed |
NCT02570516 -
NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome
|
N/A | |
Recruiting |
NCT02813824 -
Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome
|
Phase 3 | |
Recruiting |
NCT05078866 -
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT03744962 -
MSI in Circulatory DNA of Endometrial Cancer
|
||
Recruiting |
NCT04711434 -
PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients
|
Phase 3 | |
Completed |
NCT04131062 -
Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants
|
N/A | |
Recruiting |
NCT05704010 -
Videocapsule Endoscopy in Lynch Syndrome
|
N/A |